Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

MW Brinkhof; M Egger; A Boulle; M May; E Hosseinipour; E Sprinz; P Braitstein; F Dabis; P Reiss; DR Bangsberg; M Rickenback; JM Miro; L Myer; A Mocroft; D Nash; O Keiser; M Pascoe; S van der Borght; M Schechter

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

MW Brinkhof, M Egger, A Boulle, M May, E Hosseinipour, E Sprinz, P Braitstein, F Dabis, P Reiss, DR Bangsberg, M Rickenback, JM Miro, L Myer, A Mocroft, D Nash, O Keiser, M Pascoe, S van der Borght, M Schechter

Bristol Medical School (PHS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

91 Citations (Scopus)

Abstract

We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings

Translated title of the contribution	Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries
Original language	English
Pages (from-to)	1518 - 1521
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	45 (11)
Publication status	Published - Dec 2007

Bibliographical note

Other identifier: PM:17990236

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Handle.net

Persistent link

Cite this

Brinkhof, MW., Egger, M., Boulle, A., May, M., Hosseinipour, E., Sprinz, E., Braitstein, P., Dabis, F., Reiss, P., Bangsberg, DR., Rickenback, M., Miro, JM., Myer, L., Mocroft, A., Nash, D., Keiser, O., Pascoe, M., van der Borght, S., & Schechter, M. (2007). Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clinical Infectious Diseases, 45 (11), 1518 - 1521.

@article{7c49ee523d9d47ec96488c3f8141ab23,

title = "Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries",

abstract = "We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95\% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95\% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings",

author = "MW Brinkhof and M Egger and A Boulle and M May and E Hosseinipour and E Sprinz and P Braitstein and F Dabis and P Reiss and DR Bangsberg and M Rickenback and JM Miro and L Myer and A Mocroft and D Nash and O Keiser and M Pascoe and \{van der Borght\}, S and M Schechter",

note = "Other identifier: PM:17990236",

year = "2007",

month = dec,

language = "English",

volume = "45 (11)",

pages = "1518 -- 1521",

journal = "Clinical Infectious Diseases",

issn = "1537-6591",

publisher = "Oxford University Press",

}

Brinkhof, MW, Egger, M, Boulle, A, May, M, Hosseinipour, E, Sprinz, E, Braitstein, P, Dabis, F, Reiss, P, Bangsberg, DR, Rickenback, M, Miro, JM, Myer, L, Mocroft, A, Nash, D, Keiser, O, Pascoe, M, van der Borght, S & Schechter, M 2007, 'Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries', Clinical Infectious Diseases, vol. 45 (11), pp. 1518 - 1521.

TY - JOUR

T1 - Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

AU - Brinkhof, MW

AU - Egger, M

AU - Boulle, A

AU - May, M

AU - Hosseinipour, E

AU - Sprinz, E

AU - Braitstein, P

AU - Dabis, F

AU - Reiss, P

AU - Bangsberg, DR

AU - Rickenback, M

AU - Miro, JM

AU - Myer, L

AU - Mocroft, A

AU - Nash, D

AU - Keiser, O

AU - Pascoe, M

AU - van der Borght, S

AU - Schechter, M

N1 - Other identifier: PM:17990236

PY - 2007/12

Y1 - 2007/12

N2 - We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings

AB - We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings

M3 - Article (Academic Journal)

SN - 1537-6591

VL - 45 (11)

SP - 1518

EP - 1521

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

Abstract

Bibliographical note

UN SDGs

Handle.net

Fingerprint

Cite this